InterMune said it will stop using a 900-milligram dose of ITMN-191, its
hepatitis C drug candidate, in a midstage trial after patients showed elevated levels of a liver enzyme. The biotech firm is developing the product with Roche Holding.TheStreet.com| ...
[SmartBrief - 11/18/2009]